Citigroup Maintains Buy on Alnylam Pharmaceuticals, Lowers Price Target to $233
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst David Lebovitz has maintained a 'Buy' rating on Alnylam Pharmaceuticals (NASDAQ:ALNY), but lowered the price target from $266 to $233.

October 10, 2023 | 11:36 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Alnylam Pharmaceuticals' price target has been lowered by Citigroup from $266 to $233, though the 'Buy' rating is maintained.
The news is directly about Alnylam Pharmaceuticals and is likely to impact its stock. While the 'Buy' rating is maintained, which is positive, the lowering of the price target might create some uncertainty among investors, potentially impacting the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100